Vaccine & Antibody Research Laboratory

Lab Name: Vaccine & Antibody Research Laboratory

Research Interests

1) Vaccine development against cancer and infectious diseases.
2) Antibody development against emerging viral infections.
3) Studying tumor–host immune responses and the regulation.

PI and Researchers

PI: 신정임 (Jeong-Im Sin, Ph.D. 의학1호관 209호, jsin@kangwon.ac.kr, 033-250-8861)
학생: (김지윤, 최성륜, 이나경), 산학연계학생(김영현, 고해리, 이득기)

Research Summary: My studies have been primarily focused on determining: 1) the cellular and molecular bases of host immune responses to infection and cancer, 2) enhancing vaccination effectiveness through various ways, such as adjuvant strategies, immunization routes, DNA vaccines, subunit vaccines, peptide vaccines, delivery systems, dendritic cell application, and adenovirus gene delivery, 3) the underlying mechanism(s) of these applications for protective and therapeutic immunity. My current research interests are 1) to develop therapeutic vaccines against cancers of cervix, breast, colon, and skin origins, 2) to study the immune escape mechanisms of cancer cells and 3) to develop therapeutic antibodies against SFTSV (severe fever with thrombocytopenia syndrome virus), Ebola virus, Zika virus, and others. Our laboratory is in collaboration with Scripps Korea Antibody Institute (SKAI, Chuncheon) and GeneOne Life Science Inc. (Seoul).

Selected Publications

Jang HY, Han BS, Kwon B, Sin JI. 2018. Optimized gemcitabine therapy in combination with E7 peptide immunization elicits tumor cure by preventing Ag-specific CTL inhibition in animals with large established tumors. DNA & Cell Biol. doi: 10.1089/dna.2018.4319
Han BS, Jang HY, Racine T, Qiu X, Sin JI. 2018. Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein. Clin Exp Vaccine Res. 7(2):119-128.
Danishmalik SN, Sin, JI. 2017. Therapeutic tumor control of HER2 DNA vaccines is achieved by an alteration of tumor cells and tumor microenvironment by gemcitabine and anti-Gr-1 Ab treatment in a HER2-expressing tumor model. DNA & Cell Biol. Sep;36(9):801-811.
Lee, S.H., Han, B.S., Choe, J, Sin, J.I. 2017. Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production. Clin. Exp. Vaccine Res. 6(2): 31 July, 135-145.
Danishmalik, SN, Lee, SH, Sin, JI. 2017. Tumor regression is mediated via induction of HER263-71-specific CD8+ CTLs in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control. Oncotarget 8(19) 18 April, 26771-88.
Kim H, Danishmalik, SN, Sin JI, Hwang HI, Oh J, Cho YR, Lee HJ, Jeong MS, Kim SH, Hong HJ. 2016. Gene therapy using plasmid DNA expressing anti-HER2 antibody for HER2-overexpressing cancers. Cancer Gene Ther. 23: 341-7.
Kim J, Kim W, Moon UJ, Kim HJ, Choi HJ, Sin JI, Park NH, Cho HR, Kwon B. 2016. Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth. J Immunol. Mar 1;196(5):2410-23.
Lee SH, Danishmalik SN, Sin JI. 2015. DNA vaccines, electroporation and their applications in cancer treatment. Human Vaccines & Immunotherapeutics. Aug. 3; 11(8):1889-1900.
Lee SY, Sin JI. 2015. MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model. Human Vaccines & Immunotherapeutics. Aug. 3; 11(8):2012-2020.
Park JH, Kwon JG, Kim SJ, Song DK, Lee SG, Kim ES, Cho KB, Jang BI, Kim DH, Sin JI, Kim TW, Song IH, Park KS 2015. Alterations of colonic contractility in an interleukin-10 knockout mouse model of inflammatory bowel disease. J Neurogastroenterol Motil. Jan 1;21(1):51-61.
Ahn E, Kim H, Han KT, Sin JI. 2015. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model. Cancer Lett. 2015 Jan 28;356(2 Pt B):676-85.
Lee SY, Sin JI, Yoo HK, Kim TS, Sung KY. 2014. Cutaneous Mycobacterium massiliense infection associated with cupping therapy. Clin Exp Dermatol. Dec;39(8):904-7.
Kim H, Kwon B, Sin JI. 2013. Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. PLoS One. 8(12):e83765.
Nguyen CT, Hong SH, Sin JI, Vu HV, Jeong K, Cho KO, Uematsu S, Akira S, Lee SE, Rhee JH. 2013. Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine. 2013 Aug 20;31(37):3879-87.
Han KT, Sin JI. 2013. DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Clin. Exp. Vaccine Res. 2: 106-113.
Lee E, Kim J, Kim YM, Ha KS, Jeoung DI, Sin JI, Choe J. 2013. Beraprost enhances production of antigen-specific IgG isotypes without modulating germinal center B cell generation and the affinity maturation. Int Immunopharmacol. 15(4): 735-742.
Sin, JI, Kim H, Ahn E, Jeon YH, Park WS, Kwon BS. 2013. Combined Stimulation of TLR9 and 4.1BB augments Trp2 Peptide Vaccine-mediated Melanoma Rejection by increasing Ag-specific CTLs and their Infiltration into Tumor Sites. Cancer Lett. 330(2):190-199.
Kim, H, Sin, JI. 2012. Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism. Human Vaccines & Immunotherapeutics 8(11): 1714-1721.
Oh, HK, Sin, JI, Choi, J, Park, SH, Lee, TS, Choi YS. 2012. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J. Gynecol. Oncol. 23(4): 274-281.
Sin JI, Park JB, Lee IH, Park D, Choi YS, Choe J, Celis E. 2012. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides. Cancer Immunol Immunother. 61:1671-1682.